HighVista Strategies LLC holds a diversified book of 147 stocks worth $438.6M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter they opened C4 Therapeutics Inc and trimmed Abivax Sa-ADR. Their largest long position is Invesco DB Commodity Index T at 6% of the equity book.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as HighVista Strategies LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| MORGAN STANLEY | 80 / 80 | $166.4B |
| GOLDMAN SACHS GROUP INC | 80 / 80 | $80.9B |
| UBS Group AG | 80 / 80 | $46.2B |
| GEODE CAPITAL MANAGEMENT, LLC | 79 / 80 | $308.1B |
| BARCLAYS PLC | 79 / 80 | $34.9B |
| BNP PARIBAS FINANCIAL MARKETS | 79 / 80 | $17.2B |
| BlackRock, Inc. | 78 / 80 | $826.3B |
| STATE STREET CORP | 78 / 80 | $523.2B |
Ranked by how many of HighVista Strategies LLC's top 80 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Invesco DB Commdy Indx TRCK UNIT | $28.2M | 1.06M | 6.4% | —Held | |
| 2 | Abivax Sa SPONSORED ADS | $15.1M | 113.0K | 3.4% | ▼−0.2% Reduced · −223 sh | |
| 3 | Revolution Medicines Inc COM | $12.5M | 67.0K | 2.9% | ▼−3.4% Reduced · −2K sh | |
| 4 | Definium Therapeutics Inc COM SHS | $11.4M | 242.9K | 2.6% | ▲+31% Added · +57K sh | |
| 5 | Immunovant Inc COM | $10.7M | 277.9K | 2.4% | ▲+23% Added · +53K sh | |
| 6 | Praxis Precision Medicines I COM NEW | $10.1M | 30.2K | 2.3% | ▲+15% Added · +4K sh | |
| 7 | Relay Therapeutics Inc COM | $9.5M | 506.2K | 2.2% | ▲+20% Added · +84K sh | |
| 8 | Alkermes PLC SHS | $9.4M | 179.3K | 2.1% | ▲+145% Added · +106K sh | |
| 9 | Vaxcyte Inc COM | $8.7M | 149.7K | 2.0% | ▲+20% Added · +25K sh | |
| 10 | Tango Therapeutics Inc COM | $8.1M | 260.1K | 1.9% | ▲+150% Added · +156K sh | |
| 11 | Liquidia Corporation COM NEW | $7.8M | 97.9K | 1.8% | ▼−1.9% Reduced · −2K sh | |
| 12 | Cogent Biosciences Inc COM | $7.3M | 188.8K | 1.7% | ▼−4.2% Reduced · −8K sh | |
| 13 | Structure Therapeutics Inc SPONSORED ADS | $7.0M | 130.8K | 1.6% | ▲+5.5% Added · +7K sh | |
| 14 | Enliven Therapeutics Inc COM | $7.0M | 137.9K | 1.6% | ▲+89% Added · +65K sh | |
| 15 | Amylyx Pharmaceuticals Inc COM | $6.9M | 386.1K | 1.6% | ▲+9.7% Added · +34K sh | |
| 16 | Spyre Therapeutics Inc COM NEW | $6.9M | 77.8K | 1.6% | ▼−47% Reduced · −68K sh | |
| 17 | LB Pharmaceuticals Inc COM SHS | $6.9M | 211.5K | 1.6% | ▲+22% Added · +38K sh | |
| 18 | Cytokinetics Inc COM NEW | $6.6M | 78.0K | 1.5% | ▲+33% Added · +19K sh | |
| 19 | C4 Therapeutics Inc COM STK | $6.3M | 1.35M | 1.4% | ▲New New position | |
| 20 | Tyra Biosciences Inc COM | $5.9M | 184.8K | 1.3% | ▲+41% Added · +53K sh | |
| 21 | Alumis Inc COM | $5.6M | 200.0K | 1.3% | ▲+77% Added · +87K sh | |
| 22 | Pharvaris N V COM | $5.5M | 160.5K | 1.3% | ▲+64% Added · +63K sh | |
| 23 | Tarsus Pharmaceuticals Inc COM | $5.5M | 87.1K | 1.2% | ▲+66% Added · +35K sh | |
| 24 | Compass Pathways PLC SPONSORED ADS | $5.3M | 371.1K | 1.2% | ▲+1.9% Added · +7K sh | |
| 25 | Dianthus Therapeutics Inc COM | $5.0M | 51.1K | 1.1% | ▲+44% Added · +16K sh | |
| 26 | Nurix Therapeutics Inc COM | $4.9M | 203.7K | 1.1% | ▼−10% Reduced · −23K sh | |
| 27 | Axsome Therapeutics Inc. COM | $4.9M | 20.2K | 1.1% | ▼−1.2% Reduced · −254 sh | |
| 28 | Travere Therapeutics Inc COM | $4.9M | 86.2K | 1.1% | ▲+137% Added · +50K sh | |
| 29 | Vera Therapeutics Inc CL A | $4.5M | 105.9K | 1.0% | ▲+53% Added · +37K sh | |
| 30 | Nvidia Corporation COM | $4.4M | 21.8K | 1.0% | ▼−2.8% Reduced · −628 sh | |
| 31 | GH Research PLC ORDINARY SHARES | $4.3M | 158.8K | 1.0% | ▼−26% Reduced · −54K sh | |
| 32 | Palisade Bio Inc COM | $4.2M | 2.03M | 1.0% | ▲+0.6% Added · +12K sh | |
| 33 | Argenx SE SPONSORED ADR | $4.2M | 4.6K | 1.0% | ▼−7.3% Reduced · −357 sh | |
| 34 | Maze Therapeutics Inc COM | $4.1M | 136.6K | 0.9% | ▲+37% Added · +37K sh | |
| 35 | Ocular Therapeutix Inc COM | $4.0M | 408.5K | 0.9% | ▼−7.5% Reduced · −33K sh | |
| 36 | Oruka Therapeutics Inc COM | $4.0M | 41.9K | 0.9% | ▼−47% Reduced · −37K sh | |
| 37 | Dyne Therapeutics Inc COM | $3.8M | 172.0K | 0.9% | ▼−6.0% Reduced · −11K sh | |
| 38 | Edgewise Therapeutics Inc COM | $3.7M | 91.0K | 0.8% | ▼−1.0% Reduced · −935 sh | |
| 39 | Moonlake Immunotherapeutics CLASS A ORD | $3.7M | 187.9K | 0.8% | ▼−3.1% Reduced · −6K sh | |
| 40 | Insmed Inc COM PAR $.01 | $3.3M | 31.3K | 0.8% | ▲+29% Added · +7K sh | |
| 41 | Celldex Therapeutics Inc New COM NEW | $3.2M | 87.0K | 0.7% | ▼−2.7% Reduced · −2K sh | |
| 42 | Amazon Com Inc COM | $3.2M | 13.4K | 0.7% | ▼−40% Reduced · −9K sh | |
| 43 | Inventiva Sa ADS | $3.1M | 831.4K | 0.7% | ▲+35% Added · +216K sh | |
| 44 | Talen Energy Corp COM | $3.1M | 8.1K | 0.7% | ▲+161% Added · +5K sh | |
| 45 | Relmada Therapeutics Inc COM | $3.1M | 445.8K | 0.7% | ▲New New position | |
| 46 | Protagonist Therapeutics Inc COM | $3.0M | 24.5K | 0.7% | ▼−28% Reduced · −9K sh | |
| 47 | Erasca Inc COM | $2.9M | 160.3K | 0.7% | ▼−11% Reduced · −21K sh | |
| 48 | Viridian Therapeutics Inc COM | $2.9M | 159.9K | 0.7% | ▲+19% Added · +26K sh | |
| 49 | Hewlett Packard Enterprise C COM | $2.7M | 59.1K | 0.6% | ▼−34% Reduced · −31K sh | |
| 50 | Mineralys Therapeutics Inc COM | $2.3M | 86.1K | 0.5% | ▲+84% Added · +39K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1335325/holdings"
Use Arkolith to show HighVista Strategies LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.